TG Therapeutics | TGTX - Loan Capital


TG Therapeutics reported $745.14M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Amgen USD 51.89B 1.88B Mar/2026
Ardelyx USD 202.83M 696K Dec/2025
Arrowhead Research USD 1.23B 687.3M Mar/2026
Bayer EUR 30.68B 1.15B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
Curis USD 29.43M 10.69M Jun/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
Infinity Pharmaceuticals USD 0 0 Jun/2022
J&J USD 37.53B 1.91B Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
TG Therapeutics USD 745.14M 499.5M Mar/2026
Verastem USD 81.33M 31.01M Dec/2025
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025